-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that quickly paralyzes victims.
Scientists at Northwestern University have discovered for the first time a compound that eliminates the continued degeneration of upper motor neurons.
At first, Silverman, a professor of chemistry at Nishimoto University, discovered a compound NU-9 that can reduce protein misfolding in key cell lines.
The upper motor neuron is the commander-in-chief of brain movement.
In ALS, motor-initiating nerve cells in the brain (upper motor neurons) and muscles in the spinal cord control nerve cells (lower motor neurons) to die.
In ALS, motor-initiating nerve cells in the brain (upper motor neurons) and muscles in the spinal cord control nerve cells (lower motor neurons) to die.
NU-9 treatment can improve the ultrastructural integrity of mitochondria and upper motor neurons ( UMNs ) and endoplasmic reticulum ( ER )
NU-9 treatment can improve the ultrastructural integrity of mitochondria and upper motor neurons ( UMNs ) and endoplasmic reticulum ( ER )NU-9 treatment can improve the cellular structural integrity of the disintegration of the root tip dendrites of upper limb motor neurons ( UMN )
NU-9 treatment can improve the cellular structural integrity of the disintegration of the root tip dendrites of upper limb motor neurons ( UMN )NU - 9 treatment can reduce the degeneration of UMN 's upper motor neuron ( UMN ) that is caused by SOD1 in vivo toxic misfolding
NU - 9 treatment can reduce the degeneration of upper motor neuron ( UMN ) of UMN that is caused by SOD1 in vivo toxic misfoldingResearch and analysis show that NU-9 has similar drug-like pharmacokinetic properties, can improve the structural integrity of mitochondria and ER, reduce the level of mSOD1, stabilize the degraded UMN apical dendrites, and improve the exercise behavior measured by the thread-hanging test.
The results showed that the mechanism-centric and cell-based drug discovery method not only solved the key cell defect that caused UMN loss, but also discovered NU-9, the first compound to improve the health of diseased UMNs.
Mechanism-centric and cell-based drug discovery methods not only solve the key cell defects that lead to UMN loss, but also discover NU-9, which is the first compound to improve the health of diseased UMNs, mechanism-centric and cell-based The drug discovery method not only solved the key cell defect that caused the loss of UMN, but also discovered NU-9, the first compound to improve the health of diseased UMNs.
Hande Ozdinler, associate professor of neurology at Northwestern University School of Medicine, said that even though upper motor neurons are responsible for the initiation and regulation of exercise, their degeneration is an early event of ALS, but so far, there is no treatment plan to improve their health.
In fact, the NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: protein misfolding and protein clumps in the cell .
NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: protein misfolding and protein clumps in the cell NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: Protein misfolding and protein clumps in cells
After NU-9 was given, both mitochondria and endoplasmic reticulum began to restore their health and integrity, thereby improving the health of neurons.
The scientists next conducted experiments to reveal how and why the diseased upper motor neurons recovered health.
Original source:
Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana Sanchez, Gashaw M.
DOI:doi.
org/10.
1002/ctm2.
336">10.
1002/ctm2.
336 10.
1002/ctm2.
336 leave a message here